Brand and Other Names:Doribax
- Classes: Carbapenems
Dosing & Uses
Dosage Forms & Strengths
powder for injection
Complicated Intra-abdominal Infection
500 mg IV infusion over 1 hour q8hr x 5-14 days
At least 3 days IV, may switch to an appropriate PO treatment if clinical improvement noted
500 mg IV infusion over 1 hour q8hr x 10 days
Can be extended up to 14 days if concurrent bacteremia
Bronchopulmonary Infection (Orphan)
Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia
Orphan indication sponsor
- Johnson & Johnson Pharmaceutical, Research & Dev; 920 US Highway 202, P. O. Box 300; Raritan, NJ 08869
CrCl >50 mL/min: No adjustment
CrCl 30-50 mL/min: 250 mg IV q8hr
CrCl 10-30 mL/min: 250 mg IV q12hr
Other Indications & Uses
P. aeruginosa, K. pneumoniae, E. coli, Bacteroides caccae, B. fragilis, B. thetaiotaomicron, B. uniformis, B. vulgatus, Streptococcus intermedius, S. constellatus, Peptostreptococcus micros, Acinetobacter baumannii, Proteus mirabilis
<18 years: Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Transaminases elevated (1-2%)
Oral candidiasis (1%)
Renal impairment/failure (1%)
Toxic epidermal necrolysis, Stevens-Johnson Syndrome
Hypersensitivity to doripenem, beta-lactams or similar drugs
History of sensitivity to multiple allergens
May reduce serum valproic acid conc to subtherapeutic level: monitor levels frequently
Risk of Clostridium difficile-associated diarrhea on long-term use
Seizures reported with use
Not approved for ventilator-associated bacterial pneumonia (or any type of pneumonia); increased mortality when compared with imipenem/cilastatin (23% vs 16.7%); additionally, clinical response rates were lower with doripenem
Pregnancy & Lactation
Pregnancy Category: B
Lactation: unknown if excreted in breast milk; use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Inhibits cell-wall biosynthesis by inactivating multiple penicillin-binding proteins (PBPs), resulting in cell death
Stable to hydrolysis by most beta-lactamases
Penetrates into several body fluids and tissues, especially peritoneal and retroperitoneal
Protein Bound: 8.1%
Vd: 16.8 L
Half-life: 1 hr (normal renal function)
Plasma Clearance: 15.9 L/hr
Reconstitute vial with 10 mL SWI or NS; shake gently to form suspension
- Add to infusion bag containing 100 mL NS or D5W
- Shake gently until clear
To prepare 250 mg infusion soln for pts w/ renal impairment
- Remove 55 mL of soln from bag & discard
- Infuse remaining soln
Infuse over 1 hr
Store vials at 25°C (77°F)
Constituted Doribax suspension in vial may be held for 1 hr prior to transfer & dilution in infusion bag
Diluted suspension (already in infusion bag) in NS may be stored for 8 hr and in D5W for 4 hr at room temp (includes storage & infusion time) OR in either diluent for 24 hr at 2-8°C (includes storage & infusion time)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs